Progressive and sustained improvements in the extent and severity of atopic dermatitis with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis

被引：0
|
作者：
Alexis, A. F. [1 ]
Zirwas, M. [2 ]
Pinter, A. [3 ]
Adam, D. N. [4 ,5 ]
Chiricozzi, A. [6 ,7 ]
Pink, A. E. [8 ]
Mark, T. [9 ]
Tindberg, A. M. [9 ]
Silverberg, J. I. [10 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] Prob Med Res, Columbus, OH USA
[3] Univ Hosp Frankfurt Main, Clin Dermatol Venereol & Allergol, Frankfurt, Germany
[4] CCA Med Res, Ajax, ON, Canada
[5] Univ Toronto, Temerty Fac Med, Div Dermatol, Toronto, ON, Canada
[6] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, Rome, Italy
[7] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy
[8] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England
[9] LEO Pharma AS, Ballerup, Denmark
[10] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 184卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
384
引用
收藏
页码：E82 / E83
页数：2
相关论文
共 50 条
  • [1] TRALOKINUMAB PLUS TOPICAL CORTICOSTEROIDS AS NEEDED PROVIDES PROGRESSIVE IMPROVEMENTS IN EXTENT AND SEVERITY OF MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Alexis, Andrew F.
    Zirwas, Matthew
    Pinter, Andreas
    Adam, David N.
    Chiricozzi, Andrea
    Pink, Andrew E.
    Mark, Thomas
    Tindberg, Ann-Marie
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 63 - 64
  • [2] TRALOKINUMAB IN COMBINATION WITH AS-NEEDED TOPICAL CORTICOSTEROIDS PROVIDES SUSTAINED IMPROVEMENTS IN ITCH AND SLEEP IN MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Elewski, Boni E.
    Stander, Sonja
    Zirwas, Matthew
    Silvestre, Juan Francisco
    Kalia, Sunil
    Gutermuth, Jan
    Mark, Thomas
    Tindberg, Ann-Marie
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 64 - 64
  • [3] Early and sustained improvements in patient-reported outcomes with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis
    Elewski, B. E.
    Staender, S.
    Zirwas, M.
    Silvestre, J. F.
    Kalia, S.
    Gutermuth, J.
    Mark, T.
    Tindberg, A. M.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E83 - E84
  • [4] Is antibiotics prescription needed in infants with topical corticosteroids treatment for moderate-to-severe atopic dermatitis?
    Liu, Ying
    Zhou, Qian
    Dai, Wenkui
    Wang, Shan
    Liang, Yuan
    Li, Yinhu
    Shen, Chunping
    Li, Dongfang
    Li, Yunzhu
    Jiao, Lei
    Bian, Yawei
    Li, Shuaicheng
    Tang, Yi-Wei
    Ma, Lin
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [5] Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
    Edwards, Steven J.
    Karner, Charlotta
    Jhita, Tracey
    Barton, Samantha
    Marceniuk, Gemma
    Yiu, Zenas Z. N.
    Wittmann, Miriam
    HEALTH TECHNOLOGY ASSESSMENT, 2024, 28 (04)
  • [6] Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
    Hagino, Teppei
    Hamada, Risa
    Yoshida, Mai
    Fujimoto, Eita
    Saeki, Hidehisa
    Kanda, Naoko
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 3201 - 3212
  • [7] Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
    Jonathan I. Silverberg
    David N. Adam
    Matthew Zirwas
    Sunil Kalia
    Jan Gutermuth
    Andreas Pinter
    Andrew E. Pink
    Andrea Chiricozzi
    Sebastien Barbarot
    Thomas Mark
    Ann-Marie Tindberg
    Stephan Weidinger
    American Journal of Clinical Dermatology, 2022, 23 : 547 - 559
  • [8] Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
    Silverberg, Jonathan, I
    Adam, David N.
    Zirwas, Matthew
    Kalia, Sunil
    Gutermuth, Jan
    Pinter, Andreas
    Pink, Andrew E.
    Chiricozzi, Andrea
    Barbarot, Sebastien
    Mark, Thomas
    Tindberg, Ann-Marie
    Weidinger, Stephan
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (04) : 547 - 559
  • [9] Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
    Merola, Joseph F.
    Butler, Daniel C.
    Mark, Thomas
    Schneider, Shannon
    Kim, Yestle
    Abuabara, Katrina
    JAMA DERMATOLOGY, 2023, 159 (10) : 1119 - 1123
  • [10] Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
    Schloesser, Anne R.
    Shareef, Madena
    Olydam, Jill
    Nijsten, Tamar E. C.
    Hijnen, Dirk Jan
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (05) : 510 - 517
12345